Today news
The same in other media
First results from Gilead's study of experimental coronavirus drug soon
Reading now: 445
Gilead Sciences Inc., whose Covid-19 treatment has whipsawed markets amid conflicting early reports about its efficacy, is set to report the first results from a company-sponsored study of the experimental drug.
Data from the first 400 severely ill coronavirus patients being treated with remdesivir in an open-label study are expected before the end of next week.
While not expected to provide a definitive answer on efficacy, the report is likely to again trigger wide swings in Gilead’s shares and the broader market.
Options prices show investors expect a more than 9% move in the drugmaker’s stock price over the next week. Leaked results from a study out of China sent Gilead shares and the S&P 500 Index spinning lower on Thursday as
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.
COVID-19
United States
|
Cases: 46 252 513
Deaths: 750 423
Recovered: 0
|
India
|
Cases: 34 321 025
Deaths: 459 652
Recovered: 0
|
Brazil
|
Cases: 21 835 785
Deaths: 608 235
Recovered: 0
|
United Kingdom
|
Cases: 9 215 683
Deaths: 141 607
Recovered: 0
|
Russia
|
Cases: 8 494 589
Deaths: 237 619
Recovered: 0
|